1000% in 2 Monaten - DIE ERSTE - 500 Beiträge pro Seite

[FinanceCoach]

Dies ist kein Witz, NEIN, es ist mein vollkommener Ernst. Ich habe heute einen ZOCK begonnen und die Aktie der Firma

Eye Dynamics WKN 883610 OTC-BB:EYDY 0.30US$
geordert.

Das Unternehmen hat den WELTWEIT schnellsten Drogentest entwickelt, der Test funktioniert über eine Messung des Nystagmus, das Augenzittern. Hinzu kommt, dass dieser Test nur ein Bruchteil eines gängigen Drogentests kostet.

Lest auch den Artikel im SPIEGEL-Online
http://www.eyedynamics.com/Alkoholtest%20Schau%20mir%20in%20den%20Scanner,%20Kleiner!%20-%20Wissenschaft%20-%20SPIEGEL%20ONLINE.htm" target="_blank" rel="nofollow ugc noopener">http://www.eyedynamics.com/Alkoholtest%20Schau%20mir%20in%20den%20Scanner,%20Kleiner!%20-%20Wissenschaft%20-%20SPIEGEL%20ONLINE.htm

Ich setze das Kursziel aud mindestens 3$ innerhalb von 2 Monaten ab HEUTE!

STEIGT SCHNELL EIN.

1. Auftrag: Der Staat Alabama wird mit dem Drogentest ausgestattet. Das wird erst der Anfang sein. Ich erwarte HAMMERNEWS für kommenden Donnerstag.

Infos: http://www.eyedynamics.com

Kontakt: [e-mail]

ALLES ODER NICHTS!!!!

[Ariminios]

Wieso NICHTS?

Bei den Insidern stehen nur Verkäufe.

[antarra]

Ich teste meine Drogen lieber selber.

antarra

[Ariminios]

[TheAdvisorNo1]

Eye Dynamics schon + 19.25%

Glaub es geht los!! Eye Dynamics wird der BIG HAMMER!!! Traue denen ne ganze Menge zu, mehr als ENNT, bei EYDY ist einfach mehr Fundament, aber auch mehr Fantasie

TIP: KAUFEN

[TheAdvisorNo1]

THE INSIDER REPORT
Buy Recommendation: Eye Dynamics, Inc (NASD-OTC:EYDY)
Strong Buy Rating (Speculative) 35c

Now there is a way for an employer or any other type of authority to instantly inspect the condition of any employee quickly, cost efficiently and most importantly - accurately! This patented and well tested technology could prove to be not only revolutionary to its industry but, critical in preventing accidents, cutting liability costs for businesses of all types and sizes and best of all - savings hundreds of lives! Eye Dynamics Inc. (OTCBB, EYDY) has developed this product and calls it SafetyScope. What is even more exciting is that EYDY is evolving this product into a revenue model that would secure profits off each placement of the system long into the future, rather than being a "one time" revenue producer.
As exciting as SafetyScope is, it is not the only product EYDY has developed and patented. The House InfraRed/Video ENG System is another invention of this micro-cap gem and, as you read more about these two fascinating technological achievements, you will see why Eye Dynamics is worthy of a position in your micro-cap portfolio. The combination of proprietary technology along with computer software in order to produce a product that even the US government says performs with an accuracy that is second to none, makes EYDY one of the most intriguing micro-cap stories we have come across in a long time.
BUY RECOMMENDATION
The emphasis of consideration for investing in EYDY is based on several important factors:
The fact that the company has developed a recurring revenue model evolving around the SafetyScope product, creates the opportunity for substantial revenue growth immediately and well into the future. Fees will be administered "per test" and systems will be provided at no cost. This revenue model benefits not only EYDY, but also the company`s clients by cutting down on upfront expenditures. As long as the product remains a leader amongst these technologies the demand for the accurate, time-efficient level of results it produces will continue to expand. Current methods of urine testing are highly subjective to human errors such as contamination, mix-ups and other inefficiencies. Urine testing methods are also time consuming - it takes time to administer the test or obtain the sample, then it takes even more time to obtain the results, whereas a test administered by SafetyScope returns a result immediately. By providing an alternative to the potential mishandling and slow time frames of traditional urine testing SafetyScope provides an important service to society on both a safety and business level.
Additionally, the technology used in SafetyScope is proven and documented. The system has repeatedly outperformed all competitors and provides a much-needed alternative to an old and inefficient method of testing. The company has dedicated over ten years of research and development into this system, based on the company`s FDA-approved and patented medical technology.
As mentioned previously, there are a number of efficiencies provided by SafetyScope that make urine testing an outdated and inconvenient method in comparison. Currently urine-based drug testing generates over $1billion a year in revenues. By providing an alternative that is easier to use, cheaper to use and produces results faster, it is prudent to believe that a large portion of that market will be obtained by SafetyScope.
The expertise and longevity of management as a team solidifies EYDY as an exciting investment opportunity. The team has been together for over 12 years and includes a group that has experience in vital areas of business and medicine - Chairman Ron Waldorf is a renowned expert in vesticular physiology. Their expertise in eye physiology, medical product development and other core business skills adds a legitimacy not often found within the micro-cap arena.
To summarize the major points of this investment:
· Maximizing of revenue growth potential - A viable and recurring revenue model which ensures revenue growth for an extended period of time, rather than being susceptible to the moods of sales cycles and economic conditions.
· A vital technological edge over the competition - Proprietary technology that is cutting edge within the medical equipment industry. 12 years of R&D along with previous FDA approvals. A proven technology which helps fill a void to a vital social dilemma. A second product technology in which the company achieved the first major technological breakthrough in 40 years (VNG)
· Important player in a large, established market - A more efficient and convenient product ready to enter an already $1B/year marketplace and replace an old, inefficient technology.
· Skilled management with established track records of success - Management with experience in the medical industry AND in building successful businesses. A team that has been together for over 12 years.
COMPANY PROFILE
Back in 1988 two men, Ronald Waldorf and Charles Phillips, joined forces to form OculoKinetics, Inc. The goal of this merger was to combine their business and scientific backgrounds to create commercial applications of Waldorf`s expertise in vestibular physiology. In 1991 a company called Petro Plex acquired OculoKinetics in a reverse merger with OculoKinetics management taking the key positions. After changing the name to Drug Detection Systems the company finally became Eye Dynamics in 1993. The encouraging part is that Waldorf and Phillips still hold the positions of Chairman and President, respectively, and the company has two patented products which have achieved high standards of success and are leaders in their respective technologies.
Based in Torrance, CA, Eye Dynamics is engaged in the design, development, manufacture and distribution of equipment and related systems, which measure and record human eye movements in response to certain stimuli. Because the eye is such a sensitive organ, eye movements are reliable indicators of the presence of diseases, drugs, or other conditions which can adversely affect the human visual-motor systems. Eye Dynamics focuses on the central nervous system condition of nystagmus - a rapid, involuntary oscillation of the eyeball. This condition occurs in a variety of forms with a number of causes ranging from the serious (tumor of the brain or ear) to the benign (curable dizziness). Consumption of alcohol and/or drugs are also a cause of nystagmus - there is even a correlation between the degree of nystagmus and the amount of alcohol consumed. The company has developed two products which are cutting edge and revolutionary. Because of the magnitude of these achievements EYDY could be the success story of the year - and for years to come.
PRODUCTS
SafetyScope
Ask yourself this: How important would a product that could identify an impaired worker within 90 seconds be to a company that has workers involved in potentially perilous situations, or even involved in situations in which public safety is at risk? The amount of money that could be saved on insurance, workman`s comp. and other liability costs would be enormous. Not only that, people`s confidence in your company`s ability to provide a safe service -such as pilots, bus drivers, etc. - would provide a nice boost to any business. This idea isn`t as far fetched as it sounds, in fact, it`s a reality.
Time savings is the most obvious benefit of SafetyScope. Within a ninety second time-frame the technology measures 20 parameters of eye movement and pupil change. It then reports back a "Pass" or "Fail" result with incredible accuracy. The system works off a simple and safe user-friendly operation making it viable solution for any safety conscious environment. Simply put, the system is fast, economical and simple to use, positioning EYDY to be a major player within the Performance testing arena.
There are tremendous issues at question with urine testing, with the invasive nature of the latter being one of the most common. This presents another benefit of SafetyScope over UA`s, or even breath and hair sample testing. The SafetyScope simply peers into the test subject`s eye and returns a result of "Pass" or "Fail" without having intruding any deeper into a person`s lifestyle other than the fact are they impaired or not. It also presents a non-demeaning method for obtaining the results - no more "pee-while-they-watch" testing - and it`s also much more sanitary for both party`s involved.
Two factors that may come into play as critical to the success of this system are its ability to produce instant results and the fact that it is impossible to "fake" eye movements. Although not documented, urine analysis results can supposedly be altered through the intake of chemicals formulas which are sold over the counter and are totally legal. By taking these formulas the testee could return a "clean" or negative result when in fact, the result was just the opposite. There is no fooling the SafetyScope since eye movements, pupil constrictions and dilation are involuntary.
The second factor mentioned puts SafetyScope head and shoulders above any competition. If it takes 3-7 days to obtain the results of a urine test then there is the potential that someone is performing their duties WHILE under the influence of suffering from sleep depravation. By the time the results come back it could be too late. SafetyScope eliminates any chance of this ever happening by providing a result in real-time, right on the spot!
The revenue model being designed for SafetyScope puts an emphasis on optimal returns while providing the most economical way for any company to put the system to use. EYDY will place the system on a company premises and a royalty of $3 per test. Doesn`t seem like much at first but when you consider the unit has an assumed lifespan of 3-years, the company estimates that a system which costs $7,000 to manufacture will generate over $97,000 in revenues during that lifetime.
The House InfraRed/Video ENG System
It`s always encouraging for an investor to know that the company they are involved with has played a role in the development of a technology that separates them from the could-have-beens and the wannabees. This system is one of those products and something that has established EYDY as an important player in their industry.
The simplest way to explain The House InfraRed/Video ENG System is to start in the middle - ENG! Electronystagmographic (ENG) testing was originally performed by adhering electrodes to a patient`s skin to allow for data acquisition. The purpose of the test is to detect the condition of nystagmus - "a rapid, involuntary oscillation of the eyeball" (thanks Mr. Webster!). There are different levels of nystagmus and the causes can range from serious (brain or ear tumors) to benign (positional dizziness). Fairly simple right? Yes, but not so comfortable nor convenient for the patient or physician.
So in 1994 Eye Dynamics took ENG testing to a new level by gaining FDA approval of the House InfraRed/Video ENG System. This revolutionized ENG testing by replacing the old method of adhering electrodes to the patient with a lightweight, comfortable and durable goggle assembly. The patient just looks into the goggles and Ocular Motor Module (OMM) and all the tests are performed instantly. The old ENG is effectively replaced by the new technology, VNG Videonystagmography!
The system runs on a streamlined and simple software program that is the fastest test station available in the industry. It uses its proprietary Eye Position Interface Controller (EPIC) boards to "lock" onto the pupils and independently track the horizontal and vertical movements of each eye. The nystagmus is displayed in real time, saved, analyzed and printed. The four channel system comes with a 12" Quad/Video Monitor that displays both eyes on a single video screen. Incredible and important technology and also the first major technological advancement in the ENG in 40 years.
Some major benefits of the VNG:
· No skin preparation or electrode replacement.
· No calibration requirements.
· Clean tracings with no biological noise.
· Full four-channel, direct coupled ENG recordings (optional two-channel)
· Direct observation and video recording of patient`s eyes.
· Complete testing with eye open in a non-fixating environment.
· Observation of rotary or torsional nystagmus.
· Use of goggles for rotational testing and canalith repositionaing.
· Fast, easy recording, storage data analysis and report preperation.
· Reduced test times.
This system is distributed using a select group of "Special Instrument" dealers throughout the US. They utilize over 50 sales people and cover all 50 states.
<Click to see a screen shot of the actual system display!>
MANAGEMENT
Charles E. Phillips (President and a Director) -
Prior to forming OculoKinetics, Inc., Mr. Phillips operated Charles E. Phillips, Inc., a management and marketing consulting firm. His work has included assignments in marketing, operations and the initiation of start-up ventures. From 1974 to 1985, Mr. Phillips was Executive Vice President and Director of Akai America, Ltd., a consumer electronics company. His management background has encompassed marketing, new product planning, sales, advertising, finance, accounting, manufacturing, quality assurance and distribution. Mr. Phillips received a B.A. from Pepperdine College, Los Angeles, California with emphasis on Business and Speech Education, in 1956.
Ronald A. Waldorf (Chairman of the Board of Directors) -
Mr. Waldorf is active in overall policy formation and strategic planning for the Company. He is the inventor of the IR/Video ENG System, SafetyScope and EM/1 products. He also owns a patent covering closely related technology that has been licensed exclusively to the Company. Since 1969 Waldorf has been active in the field of otolaryngology, primarily in an academic research environment at the University of Florida, College of Medicine and at the University of California (Irvine), Department of Surgery. He has published numerous articles on vestibular and optokinetic research in international scientific and medical journals and was the principal investigator in a research grant funded by the National Institute of Health/National Institute on Alcohol Abuse and Alcoholism (NIH/NIAAA). Since 1981 he has acted as a consultant to clinics and hospitals in the Los Angeles area, including the House Ear Clinic. He has also consulted a Japanese company developing new technologies for eye movement detection. Waldorf earned an M.S. in from the Department of Physiology of the College of Medicine, University of Florida, in 1972.
Arnold D. Kay (Director) -
He has more than thirty years experience in finance, sales and administration. Mr. Kay was an employee of the Company from 1991 to 1994. He currently is co-owner and General Manager of Lomita Blueprint/CADWEST of Lomita, California, a software and computer imaging business focusing in design, graphics and distribution of CAD software and systems. Mr. Kay received a B.S. in Business Administration/Finance from California State University, Northridge, in 1961.
Barbara J. Mauch (Primary Product Development Engineer) -
She has been with the Company since 1989 and is responsible for product engineering and software development. Her background encompasses computer systems design and software development for access control of buildings and other properties. She served as a Director of the Company from 1991 to 1996. Ms. Mauch earned a B.S. in Mathematics from Northern Colorado University, in 1971 and completed the Master`s program in computer science at UCLA.
TECHNICAL ANALYSIS
Currently trading around the 35c - 40c range, EYDY is recovering off a failed break-out at 50c from a 4-month long saucer built between Nov `00 and Feb `01. The 5-month downtrend from the stocks high of 72c was also broken during the last attempt at 50c and a consolidation is appropriate before another attempt is launched. The stock is just about two-months into forming another saucer and this may be the most opportune time for accumulation. Technically, a move about the 50c range should lead to a try at the previous high and, based on company developments and a new focus on the SafetyScope product, a successful breakthrough is not unreasonable to expect. The MACD remains neutral so achieving momentum should be no problem with added exposure and interest.
CONCLUSION
With the broader markets showing a solid recovery it can also be expected that interest in the BB marketplace should return. Bargain hunters and speculators will be excited to find a gem like EYDY and with the expected surge in interest due to the SafetyScope product, EYDY is a great candidate for any speculative portfolio. The company is currently building an earnings model and we`ll be updating this report very soon with financials but until then, the story remains exciting enough to warrant establishing a position. Accumulation of the stock below 50c is highly recommended.
Pat Comer

[Diagonale]

Kannst du mal in einem 3-Zeiler übersetzen, was in diesem Strong Buy-Insider Report steht?

[TheAdvisorNo1]

Klar kann ich das, sogar in eine Wort:

Kaufen

[smarty7]

@FinanzTrainer
@DerBeraterNR1
Wenn ihr schon FrontRunning betreiben wollt, dann bitte nicht so primitiv! Oder sind die Chancen der Firma etwa so schlecht, daß die Ladenhüter-Aktien einfach nur noch raus müssen!?!

[TheAdvisorNo1]

Nein, das sind sie sicherlich nicht. Ich lade euch gerne ein, mit mir im Thread unter "HOT STOCKS" weiter zu posten.

DIESER WERT STEHT KURZ VOR DEM DURCHBRUCH, ich stehe zu allen vorigen Postings und lade euch ein, mit mir zu zocken.

[Diagonale]

@TheAdvisor

Danke

[smarty7]

@Finanztrainer, was sind denn Hammernews am Donnerstag? Und woher hast Du diese schlagkräftigen Nachrichten?